These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37561950)

  • 41. "And Does That Necessarily Mean Absolutely Alzheimer's?" An Analysis of Questions Raised Following Amyloid PET Results Disclosure.
    Kim JE; Tamres LK; Orbell SL; Cheng RZ; Klunk WE; Aizenstein HJ; Butters MA; McDade E; Lingler JH
    Am J Geriatr Psychiatry; 2024 Jan; 32(1):45-54. PubMed ID: 37634955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia.
    Marshall GA; Gatchel JR; Donovan NJ; Muniz MC; Schultz AP; Becker JA; Chhatwal JP; Hanseeuw BJ; Papp KV; Amariglio RE; Rentz DM; Sperling RA; Johnson KA
    J Alzheimers Dis; 2019; 67(2):757-768. PubMed ID: 30689584
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stakeholders' Views on Early Diagnosis for Alzheimer's Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group Study.
    Vanderschaeghe G; Vandenberghe R; Dierickx K
    J Bioeth Inq; 2019 Mar; 16(1):45-59. PubMed ID: 30868358
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 45. At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.
    Boess FG; Scelsi MA; Grimmer T; Perry RJ; Tonietto M; Klein G; Hofmann C; Salami M; Wojtowicz J; Lansdall CJ; Lane C; Kerchner GA; Smith J; Doody RS
    J Prev Alzheimers Dis; 2024; 11(3):537-548. PubMed ID: 38706270
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge.
    Cousins O; Schubert JJ; Chandra A; Veronese M; Valkimadi P; Creese B; Khan Z; Arathimos R; Hampshire A; Rosenzweig I; Ballard C; Corbett A; Aasland D; Velayudhan L; O'Neill M; Collier D; Awais R; Sander K; Årstad E; Howes O; Turkheimer F; Hodges A
    J Neuroinflammation; 2023 Nov; 20(1):272. PubMed ID: 37990275
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
    Largent EA; Harkins K; van Dyck CH; Hachey S; Sankar P; Karlawish J
    PLoS One; 2020; 15(2):e0229137. PubMed ID: 32053667
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amyloid PET across the cognitive spectrum in former professional and college American football players: findings from the DIAGNOSE CTE Research Project.
    Stern RA; Trujillo-Rodriguez D; Tripodis Y; Pulukuri SV; Alosco ML; Adler CH; Balcer LJ; Bernick C; Baucom Z; Marek KL; McClean MD; Johnson KA; McKee AC; Stein TD; Mez J; Palmisano JN; Cummings JL; Shenton ME; Reiman EM;
    Alzheimers Res Ther; 2023 Oct; 15(1):166. PubMed ID: 37798671
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of tau deposition using
    Bullich S; Mueller A; De Santi S; Koglin N; Krause S; Kaplow J; Kanekiyo M; Roé-Vellvé N; Perrotin A; Jovalekic A; Scott D; Gee M; Stephens A; Irizarry M
    Alzheimers Res Ther; 2022 Jul; 14(1):105. PubMed ID: 35897078
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission Tomography.
    Beyer L; Brendel M; Scheiwein F; Sauerbeck J; Hosakawa C; Alberts I; Shi K; Bartenstein P; Ishii K; Seibyl J; Cumming P; Rominger A;
    J Alzheimers Dis; 2020; 74(1):101-112. PubMed ID: 31985461
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers.
    Bensaïdane MR; Beauregard JM; Poulin S; Buteau FA; Guimond J; Bergeron D; Verret L; Fortin MP; Houde M; Bouchard RW; Soucy JP; Laforce R
    J Alzheimers Dis; 2016 Apr; 52(4):1251-62. PubMed ID: 27104896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.
    Strikwerda-Brown C; Hobbs DA; Gonneaud J; St-Onge F; Binette AP; Ozlen H; Provost K; Soucy JP; Buckley RF; Benzinger TLS; Morris JC; Villemagne VL; Doré V; Sperling RA; Johnson KA; Rowe CC; Gordon BA; Poirier J; Breitner JCS; Villeneuve S;
    JAMA Neurol; 2022 Oct; 79(10):975-985. PubMed ID: 35907254
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
    Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR;
    JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
    Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
    Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Incremental Diagnostic Value of [18F]Florbetaben PET and the Pivotal Role of the Neuropsychological Assessment in Clinical Practice.
    Spallazzi M; Barocco F; Michelini G; Morelli N; Scarlattei M; Baldari G; Ruffini L; Caffarra P
    J Alzheimers Dis; 2019; 67(4):1235-1244. PubMed ID: 30689568
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical impact of amyloid PET using
    Matsuda H; Okita K; Motoi Y; Mizuno T; Ikeda M; Sanjo N; Murakami K; Kambe T; Takayama T; Yamada K; Suehiro T; Matsunaga K; Yokota T; Tateishi U; Shigemoto Y; Kimura Y; Chiba E; Kawashima T; Tomo Y; Tachimori H; Kimura Y; Sato N
    Ann Nucl Med; 2022 Dec; 36(12):1039-1049. PubMed ID: 36194355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.
    Lingler JH; Butters MA; Gentry AL; Hu L; Hunsaker AE; Klunk WE; Mattos MK; Parker LS; Roberts JS; Schulz R
    J Alzheimers Dis; 2016 Mar; 52(1):17-24. PubMed ID: 27060950
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia.
    Weidman DA; Zamrini E; Sabbagh MN; Jacobson S; Burke A; Belden C; Powell J; Bhalla N; Roontiva A; Kuang X; Luo J; Chen K; Riggs G; Burke W
    Neurocase; 2017 Feb; 23(1):41-51. PubMed ID: 28376695
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.
    Mattsson N; Tosun D; Insel PS; Simonson A; Jack CR; Beckett LA; Donohue M; Jagust W; Schuff N; Weiner MW;
    Brain; 2014 May; 137(Pt 5):1550-61. PubMed ID: 24625697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.